



DIPIA

Developments in Protein Interaction Analysis

Boston, MA June 17-20, 2018

AGENDA

Sunday 17 June

10:00 AM – 6:00 PM	Registration Open
10:00 AM – 4:00 PM	Poster Drop-off
12:00 PM – 12:45 PM	Lunch
12:45 PM – 1:45 PM	<p>Tutorial Session I Good, Bad, or Ugly? Understanding what the data is telling you Michael Murphy and Paul Belcher, GE Healthcare, Marlborough, MA, USA</p> <p>Tutorial Session II Get the most out of your data: current data analysis approaches Olof Karlsson, GE Healthcare, Uppsala, Sweden</p>
1:45 PM – 2:45 PM	
2:45 PM – 3:15 PM	Coffee Break
3:15 PM – 4:15 PM	<p>Tutorial Session III - parallel sessions Best practices for working with low molecular weight compounds Cynthia Shuman, GE Healthcare, Marlborough, MA, USA</p> <p>Hunting high or low: choosing the appropriate immobilization strategy Anja Drescher, GE Healthcare, Munich, Germany</p>
3:15 PM – 4:15 PM	
4:15 PM – 4:30 PM	Bio-Break
4:30 PM – 6:00 PM	Workshop Session I - parallel sessions
4:30 PM – 6:00 PM	<p>Small molecules as therapeutics: from structure-activity relationship to clinical trials Binding kinetics - a key parameter for rational drug design Veronica Fridh, GE Healthcare, Uppsala, Sweden</p> <p>Developing a SPR strategy for small molecules that disrupt a protein: protein interaction Janice Villali, Sanofi Genzyme, Waltham, MA, USA</p> <p>SPR in late stage pre-clinical development Göran Dahl, AstraZeneca, Mölndal, Sweden</p>
4:30 PM – 6:00 PM	<p>SPR-based assays for comparability and potency assessment A closer look at Fc receptors and their binding properties to therapeutic antibodies Mike Willcox, Eurofins, Munich, Germany</p> <p>A new magnifying glass for CQA monitoring Giordana Bruni, Merck Serono, Rome, Italy</p> <p>Ligand binding for assessment of similarity and relative potency - perspectives of assay design and data analysis Robert Karlsson, EDPAR, Uppsala, Sweden</p>
7:00 PM	Welcome Reception



Monday 18 June

	Registration Open
7:00 AM – 8:00 AM	Breakfast
8:00 AM – 8:15 AM	Foreword
8:15 AM – 10:00 AM	Main Session I Characterization of biotherapeutics I
Keynote	Displacement of BMP9 pro-domains after receptor binding discovered via SPR Ute Jucknischke, Roche Diagnostics GmbH, Penzberg, Germany
	SPR Informs Selection of Lead Therapeutic Candidates with Desirable Binding Properties Juhi Juneja, Bristol-Myers Squibb, Waltham, MA, USA
	Development of a factor XIa-specific IgG and reversal reagent for thrombotic disease: a race against factor IX! Lauren Ely, Pfizer/Centers for Therapeutic Innovation, San Francisco, CA, USA
10:00 AM – 10:30 AM	Coffee Break & Exhibition
10:30 AM – 12:30 PM	Main Session I Low molecular weight drug discovery and characterization I
Keynote	Profiling of Compound Kinetics in Hit to Lead Drug Discovery: EED as a case study Sanjay Panchal, AbbVie, Chicago, IL, USA
	Fragment-Based Target Screening for Anti-Bacterials Peter Coombs, LifeArc, Stevenage, UK
	Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus Hyun Lee, University of Illinois at Chicago, Chicago, IL, USA
12:30 PM – 1:30 PM	Lunch
1:30 PM – 3:00 PM	Workshop Session II – parallel sessions
1:30 PM – 3:00 PM	SPR-based assays for comparability and potency assessment
	A closer look at Fc receptors and their binding properties to therapeutic antibodies Mike Willcox, Eurofins, Munich, Germany
	A new magnifying glass for CQA monitoring Giordana Bruni, Merck Serono, Rome, Italy
	Ligand binding for assessment of similarity and relative potency – perspectives of assay design and data analysis Robert Karlsson, EDPAR, Uppsala, Sweden
1:30 PM – 3:00 PM	Driving forward drug discovery with binding kinetics
	Driving Forward Drug Discovery with Binding Kinetics Matthias Frech, Merck KGaA, Darmstadt, Germany
	Optimization focused on target residence time results in TTK inhibitors with potent anti-proliferative activity Joost Uitdehaag, Netherlands Translational Research Center, Oss, The Netherlands
	Commitment to Covalency: Using Biacore to Understand and Evaluate the Biochemical Potency of Highly Optimized Irreversible Inhibitors Philip Schwartz, Takeda Pharmaceuticals, San Diego, CA, USA
3:00 PM – 4:30 PM	Poster Session I & Exhibition/Coffee Break
4:30 PM – 6:30 PM	Main Session III Assessment of critical quality attributes of biotherapeutics I
Keynote	SPR in early discovery and characterization of vaccine antigens Sumana Chandramouli, GlaxoSmithKline, Rockville, MD, USA
	The Importance of Rmax for Activity Assessment Daniel Malashock, Merck, Palo Alto, CA, USA
	SPR analytics in the Development of Biopharmaceuticals Markus Kuegler, Boehringer Ingelheim, Biberach an der Riss, Germany
6:30 PM	Dinner on your own



Tuesday 19 June

7:00 AM	Registration Open
7:00 AM – 8:00 AM	Breakfast
8:10 AM – 8:15 AM	Opening remarks
8:15 AM – 10:00 AM	Main Session II Low molecular weight drug discovery and characterization II
	Highly sensitive binding kinetics of CDK7/cyclin H by small molecules Kristin Hamman, Syros Pharmaceuticals, Cambridge, MA, USA
	Probing molecular mechanisms of metabolic enzymes using A-B-A injection method Bhamini Vaidialingam, Agios Pharmaceuticals, Cambridge, MA, USA
	SPR at AstraZeneca: Beyond affinity and kinetics Göran Dahl, AstraZeneca, Mölndal, Sweden
10:00 AM – 10:30 AM	Coffee Break & Exhibition
10:30 AM – 12:30 PM	Main Session II Characterization of biotherapeutics II
	Application of Biacore and AKTA instrumentation to the characterization and production of bispecific IgG from a common-light chain synthetic human antibody library Kevin Lindquist, Pfizer, South San Francisco, CA, USA
	Glycosylation Profiling of Biotherapeutics using Lectin Binding by SPR Wei Wang, Amgen, Thousand Oaks, CA, USA
	Application of Biacore in pH dependent Ab screening Siok Wan Gan, Chugai Pharmabody Research Pte. Ltd., Singapore
12:30 PM – 1:30 PM	Lunch
1:30 PM – 3:15 PM	Main Session III Assessment of critical quality attributes of biotherapeutics II
	Use of SPR-based Kinetic Assays for CQA assessment of Biotherapeutics LeeAnn Machiesky, MedImmune, Gaithersburg, MD, USA
	To Be Announced -
	Surface Plasmon Resonance Technology for Biopharmaceutical Drug Release and Stability Testing: Method Development, Transfer and Validation Jianhong Ma, GlaxoSmithKline, King of Prussia, PA, USA
3:15 PM – 4:30 PM	Poster Session II & Exhibition/Coffee Break
4:30 PM – 6:00 PM	Workshop Session III - parallel sessions
4:30 PM – 6:00 PM	Use of SPR in process development of biotherapeutics
	Biacore Adenovirus quantification Linnéa Nygren Babol, GE Healthcare, Uppsala, Sweden
	Early-stage SPR assays for recombinant subunit vaccine discovery and process development Markus Sack, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany
	Molecular Interaction Characterization during Early Development to Enable IND Filing Xiangdan Wang, Genentech, South San Francisco, CA, USA
4:30 PM – 6:00 PM	Small molecules as therapeutics: from structure-activity relationship to clinical trials
	Binding kinetics - a key parameter for rational drug design Veronica Fridh, GE Healthcare, Uppsala, Sweden
	Developing a SPR strategy for small molecules that disrupt a protein: protein interaction Janice Villali, Sanofi Genzyme, Waltham, MA, USA
	SPR in late stage pre-clinical development Göran Dahl, AstraZeneca, Mölndal, Sweden
7:00 PM	Gala Dinner and Poster Awards



Wednesday 20 June

7:30 AM	Registration Open
7:30 AM – 8:30 AM	Breakfast
8:30 AM – 8:40 AM	Opening remarks
8:40 AM – 9:20 AM	Poster award winner presentations
9:20 AM – 9:30 AM	Intro to main session
9:30 AM – 10:00 AM	Main Session IV From basic research to advanced applications I
	On-chip amplification of the complement cascade; functional assays to dissect disease mechanism and test therapeutics Claire Harris, Newcastle University, Newcastle upon Tyne, UK
10:00 AM – 10:30 AM	Coffee Break
10:30 AM – 12:15 PM	Main Session IV From basic research to advanced applications II
	Quantification of Lipid-Protein Interactions in the Assembly and Budding of Filoviruses Using Biacore Technology Robert Stahelin, Purdue University, West Lafayette, IN, USA
	Protein-Lipid interaction characterization via SPR Frantz Jean-Francois, National Institutes of Health/National Cancer Institute, Fredrick, MD, USA
Keynote	Tracking toxins: SPR biosensors for antibody development, screening seafood, and biomarker assays Betsy Yakes, U.S. Food and Drug Administration, College Park, MD, USA
12:15 PM – 12:30 PM	Closing remarks
12:30 PM – 1:30 PM	Lunch

gelifesciences.com/DiPIA2018

GE and the GE Monogram are trademarks of General Electric Company.

© 2018 General Electric Company.

GE Healthcare Bio-Sciences Corp. 100 Results Way, Marlborough, MA 01752, USA